COVID-19: a review of treatment strategies and candidate vaccines
Scientific Journal of Kurdistan University of Medical Sciences
; 26(5):126-150, 2021.
Article
in Persian
| CAB Abstracts | ID: covidwho-1756038
ABSTRACT
COVID-19 is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the acute respiratory syndrome, acute inflammatory response of the respiratory system, vascular injury, microangiopathy, angiogenesis, and widespread thrombosis. Four stages of COVID-19 have been determined;the first stage starts with an upper respiratory tract infection, the second stage starts by the onset of shortness of breath and pneumonia, the third stage starts by worsening of clinical symptoms followed by hyperinflammation, and the fourth stage is death or recovery of the patient. There is currently no successful treatment specifically for SARS-CoV-2 infection. Based on the pathological features and different clinical stages of COVID-19, especially in patients with moderate to severe COVID-19, the drug groups used includeed antiviral agents, anti-inflammatory drugs/anti-trauma drugs, and heparin with Low molecular weight, plasma, and hyperimmune immunoglobulin. During the emergency of the COVID-19 outbreak, clinical researchers are using a variety of possible therapies to test them. It seems that the precision medicine approach can answer the COVID-19 treatment questions. Therefore, the way to precision medicine in COVID-19 needs an extremely rapid pace. The aim of the present study was to discuss the most up-to-date effective drugs and vaccines against SARS-CoV-2 infection.
Prion, Viral, Bacterial and Fungal Pathogens of Humans [VV210]; Host Resistance and Immunity [HH600]; Pesticides and Drugs; Control [HH405]; Non-communicable Human Diseases and Injuries [VV600]; Non-drug Therapy and Prophylaxis of Humans [VV710]; coronavirus disease 2019; pandemics; viral diseases; human diseases; public health; literature reviews; medical treatment; candidate vaccines; respiratory diseases; dyspnoea; pneumonia; disease course; symptoms; inflammation; mortality; survival; patients; antiviral agents; antiinflammatory agents; heparin; drug therapy; immunoglobulins; blood plasma; blood transfusion; immunotherapy; Severe acute respiratory syndrome coronavirus 2; man; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; SARS-CoV-2; viral infections; lung diseases; dyspnea; disease progression; death rate; antivirals; heparin sulfate; heparin sulphate; chemotherapy; gamma-globulins; immune globulins; plasma (blood)
Search on Google
Collection:
Databases of international organizations
Database:
CAB Abstracts
Topics:
Vaccines
Language:
Persian
Journal:
Scientific Journal of Kurdistan University of Medical Sciences
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS